Relationship between free radicals and adenosine in the mechanism of preconditioning: are they interrelated or independent triggers?
Both free radicals (FRs) and adenosine receptor activation contribute to triggering a mechanism of preconditioning (PC) against infarction. This study examined the possibility that there is some interaction between FRs and adenosine generation during PC. In the first series of experiments, the effects of an FR scavenger, N-2-mercaptopropionyl glycine (MPG), on the interstitial adenosine level during PC and on the infarct size-limiting effect of PC were assessed in the rabbit heart in situ. PC with 5-min ischemia/5-min reperfusion limited infarct size after 30-min coronary occlusion (expressed as a percentage of area at risk, %IS/AR) from 33.2 +/- 4.7% (S.E.) to 10.8 +/- 1.1% (p < 0.05). This cardioprotection was blocked by MPG (1.5 mg/kg/min i.v.) infused before and during PC (%IS/AR = 27.4 +/- 3.6). However, the same dose of MPG did not suppress elevation of the adenosine and inosine levels in the microdialysate from the myocardium during 5-min ischemia/reperfusion. In the second series of experiments, the effect of an FR-generating system (1 mM hypoxanthine and 20 mU/ml xanthine oxidase) on the purine production was compared to that of PC in isolated rabbit hearts. Whereas PC increased the adenosine level in the coronary effluent from 0.17 +/- 0.16 microM under baseline to 1.68 +/- 0.53 microM, infusion of the FR generators over a period of 5 min did not increase the adenosine release. However, infarct size was similarly reduced by PC and by 5-min transient infusion of FR generators, and the cardioprotection by the FR generators was abolished by 300 microM MPG. These results suggest that there is no interaction between free radicals and adenosine during the trigger phase of PC in the rabbit heart.
Fukuma
T
T
Second Department of Internal Medicine, Sapporo Medical University, School of Medicine, Japan.
Miura
T
T
Suzuki
K
K
Tsuchida
A
A
Nozawa
Y
Y
Shimamoto
K
K
D000241:Adenosine / Q000378:metabolism*; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D015314:Dialysis Solutions / Q000032:analysis; D005609:Free Radicals / Q000378:metabolism*; D005998:Glycine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D006339:Heart Rate / Q000187:drug effects*; D019271:Hypoxanthine / Q000378:metabolism; D066298:In Vitro Techniques; D007288:Inosine / Q000378:metabolism; D019157:Ischemic Preconditioning, Myocardial; D008297:Male; D017551:Microdialysis; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D011817:Rabbits; D013438:Sulfhydryl Compounds / Q000494:pharmacology*
D000975:Antioxidants; D015314:Dialysis Solutions; D005609:Free Radicals; C110658:N-(2-mercaptoproprionyl)-glycine; D013438:Sulfhydryl Compounds; D019271:Hypoxanthine; D007288:Inosine; D000241:Adenosine; D005998:Glycine